IDRINOL CAPSULES 250MG
IDRINOL CAPSULES 250MG - 40 PCS
Security policy (edit with Customer reassurance module)
Delivery policy (edit with Customer reassurance module)
Return policy (edit with Customer reassurance module)
|Meldonium dihydrate||250 mg|
|excipients: potato starch - 18.125 mg; colloidal silicon dioxide - 5.5 mg; Calcium stearate - 1,375 mg|
|capsule: titanium dioxide (E171) - 2%; gelatin - up to 100%|
Description of the dosage form
The hard gelatin capsules No. 1 of white color, containing powder of white or almost white color.
Mechanism of action
- cardioprotective, metabolic.
Meldonium is an analogue of γ-butyrobetaine, inhibits γ-butyrobetine hydroxylase, reduces Carnitine synthesis and transport of long-chain fatty acids through cell membranes, prevents accumulation of activated forms of non-oxidized fatty acids - derivatives of acylcarnitine and acylcoenzyme A. in cells.
In conditions of ischemia, it restores the balance of the processes of oxygen delivery and its consumption in cells, prevents violation of ATP transport; at the same time activates glycolysis, which proceeds without additional consumption of oxygen. As a result of reducing the concentration of carnitine, the synthesis of γ-butyrobetaine, which has vasodilator properties, is enhanced.
The mechanism of action determines the diversity of the pharmacological effects of meldonium: increasing efficiency, reducing the symptoms of mental and physical overstrain, activation of tissue and humoral immunity, cardioprotective effect.
In case of acute ischemic myocardial damage, it slows down the formation of a necrotic zone, shortens the rehabilitation period.
In heart failure, it increases myocardial contractility, increases exercise tolerance, and reduces the frequency of strokes.
In acute and chronic ischemic disorders of cerebral circulation improves blood circulation in the ischemic focus, promotes the redistribution of blood in favor of the ischemic area.
Effective in the case of vascular and dystrophic pathology of the fundus.
Also characteristic is the tonic effect on the central nervous system, the elimination of functional disorders of the somatic and autonomic nervous systems in patients with chronic alcoholism during abstinence.
After ingestion is rapidly absorbed, bioavailability - 78%. Cmax in blood plasma is achieved within 1-2 hours after ingestion. Metabolized in the body to form 2 major metabolites, which are excreted by the kidneys. T1/2 when ingestion depends on the dose and is 3-6 hours.
Indications and usage
In neurology in complex therapy:
- ischemic stroke;
- hemorrhagic stroke during the recovery period;
- transient disorders of cerebral circulation;
- chronic cerebrovascular insufficiency.
In cardiology in complex therapy:
- ischemic heart disease (angina pectoris, myocardial infarction);
- chronic heart failure;
- dishormonal cardiomyopathy.
In general practice:
- reduced performance;
- physical overvoltage, incl. athletes;
- the postoperative period to accelerate rehabilitation;
- abstinence alcohol syndrome (in combination with specific therapy).
- increased intracranial pressure (in violation of the venous outflow and intracranial tumors);
- lactation period;
- children's age up to 18 years.
With care: diseases of the liver and / or kidneys.
Rarely - allergic reactions (pruritus, rash, redness and swelling of the face), dyspepsia, tachycardia, agitation, decrease in blood pressure.
Do not use simultaneously with other dosage forms containing meldonium (risk of side effects).
Enhances the effect of coronarodilating and some antihypertensive drugs, cardiac glycosides.
Due to the possible development of moderate tachycardia and hypotension, caution should be exercised when combined with Nitroglycerin, Nifedipine, alpha-blockers, antihypertensive drugs and peripheral vasodilators.
Can be combined with antianginal drugs, anticoagulants, antiplatelet agents, antiarrhythmic drugs, diuretics, bronchodilators.
Violation of cerebral circulation: in the acute phase of cerebrovascular disease, an injection form of the drug is used for 10 days, after which it is administered orally at 500 mg / day. The course of treatment is 4-6 weeks.
Chronic disorders of cerebral circulation: 500 mg / day, preferably in the morning. The course of treatment is 4-6 weeks. Repeated courses - 2-3 times a year.
In cardiology in complex therapy: 0.5-1 g per day. The course of treatment is 4-6 weeks.
Cardialgia on the background of dyshormonal dystrophy of the myocardium: 250 mg 2 times a day (morning and evening). The course of treatment is 12 days.
Mental and physical overloads (including athletes): adults, 250 mg 4 times a day. The course of treatment is 10-14 days. If necessary, repeat the treatment after 2-3 weeks.
At 0.5-1 g, 2 times a day before exercise; preferably in the morning. The duration of the course during the preparatory period is 14-21 days, during the competition period - 10-14 days.
Withdrawal alcohol syndrome: 500 mg 4 times a day. The course of treatment is 7-10 days.
Cases of overdose have not been established.
IRDRINOL is not a 1st-line drug for acute coronary syndrome; therefore, its use in the treatment of acute myocardial infarction and unstable angina in cardiology departments is not urgently needed.
Storage conditions of the drug Idrinol In a dry place, at a temperature not higher than 25 ° C.
Keep out of the reach of children.
Shelf life of the drug Idrinol